A pediatric combination vaccine, DTaP 5 -IPV/Hib (Pentacel, Sanofi Pasteur Limited, Toronto, Canada), was licensed in Canada in May 1997 and was introduced in all provinces and territories between July 1997 and April 1998. 1,2 DTaP 5 -IPV/Hib vaccine is comprised of a liquid formulation of diphtheria and tetanus toxoids, 5 acellular pertussis components (aluminum phosphate adjuvant), and inactivated poliovirus serotypes 1, 2, and 3 (DTaP 5 -IPV) used to reconstitute lyophilized Haemophilus influenzae type b (Hib) vaccine. The Hib component is comprised of purified capsular polysaccharide (polyribosylribitol phosphate; PRP) conjugated to tetanus toxoid (PRP-T). 1 The 5 acellular pertussis antigens contained in DTaP 5 -IPV/Hib vaccine are pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and 2 fimbrial proteins (types 2 and 3; FIM). During the 3-year period (1994 -1997) before the introduction of DTaP 5 -IPV/ Hib, most Canadian provinces and territories used a whole-cell pertussis combination vaccine, DTwP-IPV/Hib.
DTaP 5 -IPV/Hib vaccine is administered to children in Canada at 2, 4, 6, and 18 months of age, and DTaP 5 -IPV is given as a booster dose at 4 to 6 years. 3 DTaP 5 -IPV/Hib has been the exclusive vaccine used to immunize Canadian children 2 through 18 months of age against diphtheria, tetanus, pertussis, polio, and Hib disease during the years 1998 through 2007.
In May 1999, a tetanus and reduced diphtheria toxoids and acellular pertussis vaccine, Tdap 5 (Adacel, Sanofi Pasteur Limited), containing the same 5 acellular pertussis components as DTaP 5 -IPV/Hib vaccine, was licensed in Canada for persons aged 11 through 54 years. In May 2000, the National Advisory Committee on Immunization (NACI) stated that Tdap could be given to replace 1 dose of tetanus and diphtheria toxoids (Td) vaccine in adolescents and adults, but Tdap was not recommended for universal use. 4 In September 2003, after a consensus conference on pertussis in Canada, NACI issued a revised statement to recommend universal administration of 1 dose of Tdap for all adolescents and adults. 5 The first province to adopt Tdap 5 vaccine for administration to adolescents aged 14 to 16 years was Newfoundland and Labrador in 1999, 6 followed by Northwest Territories in 2000 7 ; British Columbia, Ontario, and Quebec in 2004; and the remainder of Canadian provinces and territories in 2005.
This report describes the epidemiology of 2 important infectious diseases, pertussis and invasive Hib disease, before and during the use of DTaP 5 -IPV/Hib and Tdap 5 vaccines in Canada. Additionally, the Canadian experiences with these vaccines will be discussed as they relate to the control of pertussis and Hib in the United States.
The immunization programs implemented to prevent pertussis and Hib infections in Canada have evolved with time. For pertussis, important milestones include the introduction of the first whole-cell vaccine in 1943, adsorbed whole-cell vaccines in the early 1980s, acellular vaccine for children in 1997, and acellular vaccine for adolescents and adults in 1999. For invasive Hib disease, important milestones include the introduction of unconjugated Hib vaccine for 2-year-olds in 1986, Hib conjugate vaccine for toddlers in 1988 and for infants in 1992, and incorporation of this component into whole-cell and acellular pertussis combination vaccines in 1992 (DTwP-Hib), 1994 (DTwP-IPV/Hib), and 1997 (DTaP 5 -IPV/Hib).
Historical Perspective of the Epidemiology of Pertussis in Canada
Pertussis ("whooping cough") has been a reportable disease in Canada since 1924. A case of pertussis is reported by Canadian health authorities when Bordetella pertussis is grown from an appropriate clinical specimen or identified by a polymerase chain reaction (PCR) assay. Alternatively, a case is reported when the patient is epidemiologically linked to a laboratory-confirmed case and the patient has one or more of the following symptoms for which there is no other known cause: paroxysmal cough of any duration, cough ending in vomiting or associated with apnea, or cough with inspiratory whoop. 8 Before the introduction of whole-cell vaccine in Canada, pertussis was a major cause of death among young children (primarily, infants Ͻ1 year) and a source of serious complications, including pneumonia, seizures, and encephalopathy. 3 Historically, cyclic peaks of pertussis incidence occurred approximately every 3 to 5 years, with major outbreaks occurring in the mid-1930s to early 1940s. These epidemiologic patterns are similar to those observed in the United States and worldwide.
After the introduction of whole-cell pertussis vaccine in 1943, a sharp decline of cases was reported in Canada followed by a slower but steady decline between the mid-1950s and early 1970s. The reported incidence decreased from 160 to 180 cases per 100,000 in the 1930s to Ͻ20 cases per 100,000 during the 1970s and through the mid 1980s (Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/A969 ). 3, 9 Before the introduction of whole-cell vaccine, pertussis occurred most commonly among children aged 1 to 5 years, with fewer than 20% of cases reported among infants. 10 Availability of whole-cell pertussis vaccine precipitated an overall decline of reported cases among preschool and young school-aged children and prevented widespread outbreaks in the general population. A consequence of whole-cell vaccine use was a shift of the disease burden to infants Ͻ1 year of age and a modest increase of disease among adolescents and young adults. 9, 10 During the late 1980s and early-to-mid 1990s, a resurgence of pertussis was reported among all age groups in Canada, resulting from a number of factors, including relatively low efficacy of the whole-cell vaccine used during that time, waning vaccine-and natural infection-induced immunity among adolescents and adults, and increased physician awareness, diagnosis, and reporting of the disease. 9, 10 The increase in case reports during the 1990s was not associated with any decline of immunization rates among Canadian children. 11 Children who were given whole-cell vaccine during 1980 to 1997 constitute a cohort that to the present day report persistently elevated rates of pertussis.
Historic Perspective of the Epidemiology of Invasive Hib Disease in Canada
Hib meningitis has been reportable nationally in Canada since 1979 and all other invasive Hib diseases have been reportable since 1986. The current definition of a laboratory-confirmed case of invasive Hib disease includes any patient with isolation of Hib from a normally sterile body site or from the epiglottis in a patient with epiglottitis, or demonstration of Hib antigen in cerebrospinal fluid. 8 Before introduction of effective Hib vaccines in the late 1980s and early 1990s, 1 in 200 -250 Canadian children younger than 5 years developed invasive Hib infection; 3% to 5% of these children died. 12 The majority of cases occurred in children 6 to 24 months of age and meningitis comprised 55% to 65% of all reported Hib cases. 3, 12 During the prevaccine era, Hib was the most common cause of bacterial meningitis in young children, resulting in severe neurologic sequelae in 10% to 15% of survivors and deafness in 15% to 20%. It was also a major cause of potentially life-threatening epiglottitis, septicemia, cellulitis, pneumonia, septic arthritis, and pericarditis.
The first Hib vaccine, unconjugated PRP, was licensed in Canada in 1986, but its ability to protect children was limited because it was not consistently immunogenic in those under 24 months of age. 12 PRP was replaced in 1988 by PRP-diphtheria toxoid conjugate (PRP-D) vaccine administered at 18 months of age, which later was proven to have an efficacy of only 74% to 88%. 12 More effective Hib conjugate vaccines were introduced in 1991 for use in toddlers and in 1992 for infants starting at 2 months of age. Hib conjugate vaccines contributed to a steep decline of cases during the late 1980s and early 1990s. PRP-tetanus toxoid conjugate (PRP-T) vaccine has been the Hib vaccine used in all Canadian provinces and territories since 1995, as a component of either whole-cell or acellular pertussis combination vaccines.
Epidemiology of Pertussis in the Last 2 Decades in Canada
Although the incidence of pertussis in Canada had decreased Ͼ90% compared with the peaks in the 1930s to 1940s, rates increased significantly in the late 1980s and early 1990s. 13 An epidemiologic investigation of an outbreak of pertussis in Nova Scotia in 1994 revealed that the effectiveness of the whole-cell vaccine used in the region was only 57% against laboratoryconfirmed pertussis among children Ն4 years who had received 5 doses of vaccine compared with partially immunized or nonimmunized children. 13 Similar effectiveness was found among children attending child care centers (56%) and schools (51%) in Quebec.
14 Potential explanations for the less-than-optimal performance of the Canadian whole-cell vaccine include a relatively poor antibody response to PT or interference between the pertussis and poliovirus components in the combined vaccine. Concerns related to the vaccine's effectiveness and safety led to the decision to replace the whole-cell (DTwP-IPV/Hib) vaccine with an acellular (DTaP 5 -IPV/Hib) vaccine in 1997. The DTaP 5 components of the acellular vaccine had been tested in an efficacy trial in Sweden in 1992 to 1995 and had demonstrated a superior safety profile compared with the DTwP control, with an efficacy of 85% against World Health Organization-defined pertussis (ie, Ն21 consecutive days of paroxysmal cough with laboratory confirmation of B. pertussis). 15 Clinical trials of DTaP 5 -IPV/Hib vaccine in Canada further confirmed the safety and immunogenicity of this combination product. 16 Both passive and active surveillance systems have documented a significant decline of reported pertussis cases and incidence rates among Canadian children since the introduction of DTaP 5 -IPV/Hib vaccine. In the national Notifiable Disease Reporting System (NDRS), confirmed cases are reported by provincial health authorities to the Public Health Agency of Canada (PHAC). As shown in Figure 2 , typical cyclical peaks of pertussis incidence were observed in 1990, 1994 -1995, and 1998. Based on the usual 3 to 5 year cycles, another peak was expected between 2001 and 2003, but none occurred. In fact, there has been no new peak since national introduction of DTaP 5 -IPV/Hib vaccine was completed in 1998.
From October 2005 to March 2006, a laboratory-confirmed outbreak of pertussis occurred primarily in preschool-aged children isolated to the Toronto region and not observed elsewhere in Canada. There was an almost 6-fold increase in the absolute number of positive respiratory specimens and more than 2-fold increase in the percentage of respiratory specimens positive by PCR for B. pertussis compared with the previous year. Although the isolation of B. pertussis was confirmed by culture in only a small minority of cases (Ͻ3%), the PCR results were validated with multiple laboratories using different methodologies and showed that the outbreak was not due to contamination in the laboratory, as has been previously described in pseudo-outbreaks of pertussis. 17, 18 This was not, however, a classic pertussis outbreak. Most of the cases were preschool children previously immunized with an effective acellular pertussis (DTaP 5 -IPV/Hib) vaccine. In addition, despite evidence that B. pertussis was widely circulating in the Toronto community, only 1 unimmunized infant case was hospitalized for an illness requiring intubation and mechanical ventilation, secondary to RSV and B. pertussis coinfection. In addition, although the proportion of cases that met a clinical case definition for pertussis (42%) was significantly higher in cases than controls, it was considerably lower than the percentage of cases meeting a clinical definition in other reported pertussis outbreaks (Ͼ80%). 19, 20 In contrast to other studies reporting a secondary attack rate of 20% to 29% in children 0 through 4 years, 21, 22 the secondary attack rate in this outbreak was only 8%. Moreover, an alternate respiratory organism was identified in one-third of cases, suggesting that at least in this subset of cases, symptoms may have been due to a cause other than B. pertussis. This was likely a milder pertussis outbreak that may have been moderated by high vaccination rates and may have been inflated to some degree by transient nasopharyngeal carriage of B. pertussis.
After the last national peak of pertussis disease in Canada in 1998, reported cases decreased substantially among children aged 1 through 9 years (Fig. 2) . 23 Between 1998 and 2004 (the last year for which PHAC data are available), the rate of pertussis among children aged 1 through 4 years declined from 118.6 cases per 100,000 to 21.7 cases per 100,000, representing an 81.7% reduction. Comparable reductions were observed among children aged 5 through 9 years, with an 86.9% decline between 1988 and 2006 (149.1 cases per 100,000 to 19.4 cases per 100,000). The highest incidence, morbidity, and mortality associated with pertussis in Canada occurred among infants Ͻ12 months of age. The incidence rates in this age group have remained steady since 2001 (range, 71.3-91.6 cases per 100,000) and the majority occur among those who are Ͻ6 months of age, too young to have completed the infant vaccination series.
9,10 Of 19 pertussis-related deaths between 1989 and 2000 in Canada, 16 were infants; all but 1 of the infants was younger than 3 months of age, and only 1 had received any vaccination. 9 The overall effectiveness of DTaP 5 -IPV/Hib vaccine in reducing the occurrence of pertussis has been further documented by investigators participating in the Immunization Monitoring Program, Active (IMPACT), through active disease surveillance of inpatients at 12 tertiary care hospitals in Canada. The IMPACT network encompasses 90% of tertiary care pediatric beds in Canada and includes data on hospitalized children from birth through 16 years of age. Patients from all Canadian provinces and territories may be transferred to IMPACT centers for care depending on the severity of disease and referral patterns. A nurse monitor assigned to each hospital conducts disease surveillance by reviewing microbiology records and daily admissions and discharges. 24 Bettinger et al 2 recently reviewed the IMPACT pertussis database for the period of January 1991 through December 2004. During this time, there were 2096 pertussis admissions in IM-PACT centers: 1174 during the whole-cell era (children who received DTwP-combination vaccines during [1991] [1992] [1993] [1994] [1995] [1996] and 842 during the acellular era (children who received DTaP 5 -IPV/Hib vaccine during 1999 -2004); 80 who might have received either whole-cell or acellular vaccine during the transition period, 1997 to 1998, were excluded from analysis. Among children aged 1 through 4 years, the incidence of pertussis leading to hospitalization decreased approximately 85% from the wholecell period to the acellular period (4.6 -0.7 cases per 100,000 population). In addition, after the switch to DTaP 5 -IPV/Hib vaccine, the typical 3-to 5-year peak did not recur in children older than 1 year. 2 Compared with the whole-cell vaccine era, the preponderance of hospitalized cases during the acellular era shifted to younger age groups, primarily infants too young to have been immunized (Ͻ2 months of age; 39.0% in the acellular era vs. 26.1% in the whole-cell era; P Ͻ 0.0001) or too young to have received a second dose (2-3 months of age; 42.9% vs. 34.2%; P Ͻ 0.0001). 2 At the same time, there was a decline in the proportion of hospitalized cases that occurred among children old enough to have received 2 to 3 doses of vaccine (4 -11 months of age; 15.1% acellular era vs. 27.3% whole-cell era) and among 6-to 23-month-old children appropriately vaccinated for age (vaccine failures; 2.3% vs. 11.4%; P Ͻ 0.0001). Of 17 fatalities, only 1 received any vaccine (a 9-week-old who received 1 dose of whole-cell vaccine) and all but 1 (a 6-month-old) were Յ10 weeks of age. Figure 3 shows the IMPACT data through 2006, demonstrating a continued decline of hospitalized cases of pertussis during the DTaP 5 -IPV/ Hib era.
IMPACT data during 1995 through 2001 also demonstrated significant reductions during the acellular era in the rates of hospitalizations for febrile seizures (79%) and for hypotonichyporesponsive episodes (60%-67%), temporally associated with pertussis vaccination compared with the whole-cell era. 25 A remarkable change in the epidemiology of pertussis has occurred among a unique and apparently susceptible cohort of children in Canada. Between the early 1990s and the present, the peak age of pertussis disease has increased in step with the aging of the population of children who were vaccinated with whole-cell vaccine before the introduction of DTaP 5 -IPV/Hib vaccine in 1997 to 1998. Skowronski et al 10 were the first to observe this effect by analyzing data from outbreaks occurring in British Columbia in 1990 Columbia in , 1993 Columbia in , 1996 , and 2000. During successive outbreaks, the proportion of cases decreased among infants Ͻ1 year and children 1 through 4 years, while the proportion increased among adolescents and adults. Compared with an outbreak in 1996, a greater proportion of cases were reported among 10-to 19-year-olds during a subsequent outbreak in 2000 (12% in 1996 vs. 34% in 2000). The median age of pertussis cases shifted from 5 years in 1993 to 6 years in 1996 to 11 years in 2000. 10 Data from the British Columbia Centre for Disease Control now extend through 2006 ( The same phenomenon of a marching age cohort also has been described by Halperin, 26 who analyzed data for the entire country. Each year, from 1989 through 2004, the age of peak incidence increased by 1 year, demonstrating that children given whole-cell vaccine in the 1980s to mid-1990s remained at substantially higher risk of contracting pertussis compared with children given acellular pertussis vaccine (DTaP 5 -IPV/Hib). Excluding infants Ͻ1 year, the peak incidence of pertussis occurred 
Adolescent and Adult Tdap 5 Vaccine
Tdap 5 was licensed in Canada in 1999, but NACI did not recommend universal use of the vaccine for adolescents and adults until 2003. 5 The universal program goals were to protect adolescents and adults and to "decrease the morbidity and mortality of pertussis across the entire lifespan". In addition, NACI hoped that the program would help protect infants by reducing their exposure to the organism.
Newfoundland and Labrador (1999) and Northwest Territories (2000) adopted Tdap 5 vaccine before the universal recommendations were issued. Newfoundland and Labrador instituted universal administration of Tdap 5 vaccine to all ninth grade children (14 -16 year olds) beginning in September 1999. 6 A schoolbased immunization program achieved an overall coverage rate of 95% by 2005. Pertussis outbreaks occurred in this region in 1994, primarily among 1-to 9-year-olds, and in 1999, primarily among 5-to 9-year-olds. Since the introduction of Tdap 5 vaccine, the only subsequent outbreak occurred in 2003. Most of the cases in 2003 were reported among 10-to 14-year-olds, but there were no cases among children who had received Tdap 5 . In 2004, only 5 cases were reported across all age groups. 6 It may be that the addition of Tdap 5 vaccine for adolescents contributed to the reduced overall case reports, but a substantial number of cases reported during the 2003 outbreak occurred among adults, suggesting that the NACI recommendations to immunize all adults with Tdap should be implemented.
In October 2000, Northwest Territories was the second region to adopt Tdap 5 vaccine, with universal implementation for all 14-to 16-year-olds in early 2001. 7 Large pertussis outbreaks occurred in 1993 and 1999 and a small outbreak was seen in 1996, but no outbreaks were observed after introduction of Tdap 5 in 2001. The overall incidence of pertussis across all age groups decreased from 7.5 cases per 10,000 population during 1993-1996 (whole-cell era) to 7. In 2004, British Columbia adopted Tdap 5 with administration of the vaccine to all 14-to 16-year-olds. In the short time since its introduction, the pertussis incidence among 15-to 19-year-olds decreased from 45 cases per 100,000 in 2003 to 7 cases per 100,000 in 2006, representing an 84% decline from the peak. 27 Among 10-to 14-year-olds, incidence rates decreased from 149 cases per 100,000 in 2003 to 24 cases per 100,000 in 2006 (84% reduction), suggesting that Tdap 5 vaccination might be having an effect on pertussis disease among the adolescent population. The decline among 10-to 14-year-olds also may reflect some residual protection from their toddler and preschool booster doses of acellular vaccine (relative to the earlier cohort who received only whole-cell vaccine) or possibly herd immunity from Tdap 5 vaccine use among older adolescents. 
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Epidemiology of Invasive Hib Disease in the Last 2 Decades in Canada
By the time DTaP 5 -IPV/Hib combination vaccine was licensed in 1997, the reported incidence of invasive Hib disease among children Ͻ5 years had already decreased by Ͼ95%, compared with the pre-Hib vaccine era, as a result of widespread use of Hib conjugate vaccines. 3 Since 1998, when DTaP 5 -IPV/Hib vaccine was adopted by all provinces and territories, the incidence of Hib disease in this vulnerable age group has remained very low, Ͻ1 case per 100,000 children each year (range, 0.44 -0.91 cases per 100,000 per year; Fig. 6 ). 23 Comprehensive reports of invasive Hib disease have been published from investigators of the IMPACT surveillance network. The estimated number of children with invasive Hib disease in IMPACT hospitals decreased from 485 cases in 1985 to an average of fewer than 10 cases per year since 1997, a decrease of Ն98% (Fig. 7) . 12, 28 A steady decline of cases was reported from 1988 to 1992, when PRP-D vaccine was given to toddlers, and a steep decline occurred from 1992 to 1993 when Hib conjugate vaccines were introduced for infants. 12 During 1991-1994, 36 cases were considered vaccine failures; 3 among recipients of unconjugated PRP vaccine, 27 after PRP-D vaccine, 3 after PRP-T vaccine, and 3 after other Hib vaccines. 12 Scheifele et al 28 summarized their data for 29 Hib cases reported in the IMPACT network during [2001] [2002] [2003] . Fifteen (52%) of the children were Ͻ12 months of age, 9 (31%) were 1 through 5 years, and 5 (17%) were Ն6 years; 20 (69%) were male. Fifteen (52%) were diagnosed with meningitis, 6 (21%) with pneumonia and bacteremia, 4 (14%) with epiglottitis, and 4 (4%) with other invasive diseases. The overall case fatality rate was 7%. Among the 29 cases, only 2 were considered vaccine failures (defined as occurring at least 4 weeks after completing the primary series) in previously healthy children; 7 failures occurred in children who were immunocompromised or had chronic underlying medical conditions. In contrast, 20 of the cases had no or incomplete vaccination, including 11 who were too young to have completed the primary series, 7 due to parental refusal (including 1 who was also too young to complete the series), 2 due to delayed completion of the primary series, and 1 had an uncertain but incomplete vaccination history. Of 5 children who had received 4 age-appropriate doses of DTaP 5 -IPV/Hib vaccine, 4 had predisposing conditions and 1 was previously healthy. 28 A similar pattern was observed when the IMPACT investigators compiled their data for 24 Hib cases reported during 2004 through 2007. 29, 30 Fifteen (63%) of the 24 children were incompletely immunized: 11 were too young to complete the primary series of DTaP 5 -IPV/Hib vaccine (Ͻ12 months of age) and 4 were unimmunized by parental choice (2-5 years). 30 Three cases were considered vaccine failures after 3 doses, including 2 children who were Ն24 months of age and had not yet received a toddler booster dose. Five cases were considered vaccine failures after 4 doses, including 3 noncompromised children (2, 6, and 6 years of age) and 2 who were immunocompromised (6 and 9 years of age). One additional case occurred in a 17-year-old previously given 1 dose of PRP-D vaccine at 2 years of age. The estimated incidence rate for children aged 0 to 16 
Hib Disease in High-Risk Populations
Certain socio-ethnic populations are at substantially higher risk for Hib disease and its potentially life-threatening complications. These populations include native inhabitants in both Canada (including Inuit, First Nations, and Métis; collectively referred to as Aboriginals) and the United States (including Eskimo, Inuit, and Aleut; collectively referred to as Alaska Native). 31, 32 The PHAC and the Arctic Investigations Program of the CDC maintain joint surveillance in the polar region of both countries. Since 1999, the PHAC and Arctic Investigations Program have participated in a larger network of public health agencies, hospitals, and reference laboratories in 8 countries that are located, at least in part, in the arctic region, known as the International Circumpolar Surveillance (ICS) program. 33 The Aboriginal population under surveillance in the polar region of Canada (Yukon, Northwest Territories, Nunavut, northern regions of Labrador, and Quebec) is approximately 78,400 persons, and the Native population under surveillance in Alaska is approximately 124,500 persons (Table 1) . 32 During comparable 5-year periods of surveillance (the most recent years in each country for which complete ICS data are available), DTaP 5 -IPV/Hib vaccine was used in Canada (2000 - 
H. influenzae Nontype b Disease
The occurrence of invasive Hib disease has been so rare in recent years that nontype b strains have become the focus of several reports from Canada. In Manitoba, among 52 H. influenzae strains isolated from patients with invasive disease during 2000 -2004, only 3 (6%) were serotype b, whereas 26 (50%) were serotype a, 3 (6%) were other serotypes, and 20 (38%) were nontypeable. 36 In a follow-up report, Tsang et al summarized their data from Manitoba for the period of 2000 through 2006. 37 The database was expanded to 122 isolates of H. influenzae; 36 (30%) were serotype a, 5 (4%) were Hib, 12 (10%) were other serotypes, and 69 (57%) were nontypeable. The majority of serotype a cases (72%) occurred in infants Ͻ24 months of age. Of the 5 Hib cases, 4 occurred in infants Ͻ12 months of age (vaccine histories and age of onset not available) and 1 occurred in a 52-year-old adult.
In a recent review of IMPACT data for 1996 through 2001, 166 H. influenzae strains were characterized from children diagnosed with invasive disease. 38 Eighty-nine (54%) were caused by nontype b serotypes, 58 (35%) were Hib, and 19 (11%) were not serotyped. Among the 89 nontype b cases, 47 (53%) were nontypeable, 25 (28%) were caused by serotype a, 11 (12%) serotype f, 4 (4%) serotype d, and 2 (2%) serotype e. The majority of the serotype a cases (20 ͓80%͔) occurred in infants Ͻ1 year of age, 24 (96%) occurred in 4 western Canadian provinces, and 19 (76%) occurred among Aboriginal children. 38 Of the 58 Hib cases, 21 (36%) were classified as vaccine failures (14 received PRP-T vaccine ͓in whole-cell or acellular pertussis combination vaccines; number of each not reported͔ and 7 received PRP-D or PRP vaccine), 21 (36%) received no Hib vaccine, and 16 (28%) were incompletely vaccinated for age. 38 A similar shift of serotypes has occurred in the arctic region. 
DISCUSSION
During the past decade, DTaP 5 -IPV/Hib vaccine was the exclusive vaccine administered to Canadian infants and toddlers to protect them against diphtheria, tetanus, pertussis, polio, and Hib infections. Pertussis and invasive Hib disease have been wellcontrolled, as reflected by reduced rates of these diseases in national, provincial, and IMPACT data. 2, 27, 28, 40 The national decline in incidence rates of pertussis among preschool and school aged children after 1998 demonstrates the effectiveness of the acellular pertussis components of the DTaP 5 -IPV/Hib combination vaccine. The decline of pertussis among adolescents in provinces and territories that have adopted universal Tdap 5 immunization programs for 14-to 16-year-olds indicates that Tdap 5 vaccine is effective in this population. 15 The estimated efficacy of DTaP 5 vaccine in the Sweden trial was 85% against WHO-defined pertussis (laboratory confirmation and Ն21 consecutive days of paroxysmal cough) and 78% against pertussis of any severity including mild disease (laboratory confirmation and Ն1 day of cough).
National, IMPACT, and regional surveillance data confirm very low rates of invasive Hib disease in Canada, with an average of only 3 breakthrough cases (after receipt of 3 or 4 DTaP 5 -IPV/ Hib vaccine doses) occurring each year among approximately 1.7 million Canadian children younger than 5 years. 28 Even among Aboriginal children, cases of Hib disease are rare; only 3 occurred among these high-risk children in a 5-year period. 34, 35 Most Hib cases in Canada are reported among children with no or incomplete vaccination or in children who have an underlying medical condition, including various causes of immunodeficiency. 28 The epidemiology of pertussis and invasive Hib disease are similar in the United States and Canada. As in Canada, whole-cell vaccines were introduced in the United States in the 1940s, leading to a Ͼ99% decline in the incidence of reported pertussis cases from a peak of approximately 150 cases per 100,000 population in the prevaccine era. 44 A nadir was reached when only 1010 cases were reported in 1976. 45 However, since the early 1980s, reported pertussis cases have steadily increased, reaching 25,827 cases in 2004, the highest number since 1959. 45 Reported cases have increased among all age groups, but most dramatically among adolescents and adults. In recent years, two-thirds of the total cases reported in Canada and the United States have been among adolescents and adults. 23, 46, 47 In the United States, the increase in pertussis case reports has been ascribed to waning immunity after childhood vaccination; to increased awareness among physicians, other healthcare professionals, and the public; to improved availability of diagnostic tools; and to lower protection afforded by previously used whole-cell vaccine. 44, 48 Despite increased numbers of reported pertussis cases, underreporting remains a major issue for all age groups, but perhaps more so for adolescents and adults because of the often atypical appearance of their illness. Based on recent epidemiologic studies, between 800,000 and 3.3 million cases of pertussis are estimated to occur among adolescents and adults in the United States annually. 49 As with pertussis, the epidemiology of invasive Hib disease in the United States is similar to that of Canada. Although reporting was not complete in the early 1980s, approximately 1 case of Hib disease is estimated to have occurred per 200 to 250 children less than 5 years in both the United States and Canada before availability of Hib vaccines. 3, 50 Hib vaccine introduction in the United States followed a timeline similar to that of Canada: unconjugated PRP vaccines were introduced for 18-month-olds in 1985 and Hib conjugate vaccines for toddlers in 1988 and infants in 1990 to 1991. 50 As in Canada, the use of these vaccines in the United States led to a marked decline of the reported incidence of Hib disease in the late 1980s and early 1990s. In Canada, except for a brief period following the introduction of several types of Hib conjugate vaccines for infants in 1992, PRP-T vaccine has been the exclusive Hib vaccine used in Canada, first in the whole-cell combination vaccines and then in the acellular pertussis combination DTaP 5 -IPV/Hib vaccine used since 1997. In contrast, in the United States, 3 Hib conjugate vaccines were used for many years after their introduction in the early 1990s: PRP-T, PRP-OMP, and HbOC (PRP conjugated to a mutant form of diphtheria toxoid; Wyeth, Pharmaceuticals Inc, Philadelphia, PA; distribution in the United States stopped in 2004).
Historically, the antibody response to the Hib component in combination vaccines has been a concern. 51 In trials conducted in the 1990s, vaccines that combined Hib with DTaP vaccines, other than the Canadian 5-component acellular pertussis vaccine, induced antibody responses to the Hib component that were significantly lower than responses achieved when DTaP and Hib vaccines were administered separately. 52 In contrast, studies of DTaP 5 -Hib combination vaccines using the Canadian 5-component acellular pertussis vaccine have demonstrated no immunologic interference, and these results have been confirmed by the effectiveness of DTaP 5 -IPV/Hib vaccine against invasive Hib disease in Canadian children, including high-risk Aboriginals. 16, 28, 34, 35, 42, 53 In US clinical trials, DTaP 5 -IPV/Hib vaccine generated antibody responses to the diphtheria, tetanus, pertussis, polio, and Hib components comparable to those achieved by separately administered US-licensed DTaP 5 , IPV (IPOL; Sanofi Pasteur Limited), and Hib (ActHIB; Sanofi Pasteur SA, Lyon, France) vaccines. 42 Given the similar epidemiologic patterns of disease in Canada and the United States, the similar immunization schedules and vaccine coverage rates in the 2 countries, and the similar antibody responses to the pertussis and Hib components in DTaP 5 -IPV/Hib vaccine compared with separately administered DTaP 5 and Hib vaccines, DTaP 5 -IPV/Hib is expected to provide the same level of protection in the United States as experienced with this combination vaccine in Canada, and as currently experienced in the United States with separate vaccines.
